Product Description
Besifloxacin ophthalmic is used to treat bacterial conjunctivitis (pinkeye; infection of the membrane that covers the outside of the eyeballs and the inside of the eyelids). Besifloxacin is in a class of medications called fluoroquinolones. It works by killing the bacteria that cause infection. (Sourced from: https://medlineplus.gov/druginfo/meds/a610011.html)
Mechanisms of Action: DNA Gyrase Inhibitor,TOP4 Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Ocular,Topical,Ophthalmic
FDA Designation: None *
Approval Status: Approved
Approved Countries: Argentina | Australia | Bangladesh | Brazil | Canada | Colombia | Egypt | India | Jordan | Lebanon | Malaysia | Mexico | Singapore | South Africa | Taiwan | Thailand | Turkey | United Arab Emirates | United States | Vietnam
Approved Indications: None
Known Adverse Events: None
Company: None
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|